The Week at Ropes & Gray: Pfizer’s $14 Billion Acquisition and a Burst in Dealmaking, Anti-Corruption Risk in the Real Estate Sector, and a First Pitch at Fenway
The dealmakers were busy this week, headlined by Pfizer Inc. (represented by Ropes & Gray), which announced two acquisitions: Medivation Inc., the San Francisco-based biotech company that focuses on cancer drugs, for $14 billion, and the small molecule antibiotics business of AstraZeneca.
Just in time for the uptick in deal activity, Ropes & Gray’s M&A team released “The Ropes Recap,” a quarterly recap of mergers & acquisitions law news, including news from the courts; Delaware legislative, tax and SEC updates; and a focus on the UK.
Coming up: Ropes & Gray is co-sponsoring, with Chambers, a seminar “Navigating the Enforcement Landscape,” on Sept. 13 in New York City. Ropes & Gray attorneys will be joined by government attorneys and in-house counsel in discussing critical areas facing companies, financial institutions and asset managers in a global environment and providing practical guidance on how best to navigate these complex problems. Register here.